Literature DB >> 17414536

Lupoid sclerosis: what is the role of antiphospholipid antibodies?

Isabella Lima1, Ailton Melo, Ivar Viana Brandi, Olívia Costa, Mittermayer Santiago.   

Abstract

A multiple sclerosis-like syndrome, also called lupoid sclerosis for having some lupus characteristics, has been described in a few reports. Recently, antiphospholipid antibodies have been demonstrated in patients with this syndrome, suggesting that they can participate in the etiopathogenic process, which can have therapeutic implications. We report the case of a patient previously diagnosed with multiple sclerosis who later presented with ANA positivity and antiphospholipid antibodies, livedo reticularis, and deep venous thrombosis, leading her to be characterized as having lupoid sclerosis. The patient was anticoagulated. Antiphospholipid antibodies may be involved in the pathogenesis of lupoid sclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414536     DOI: 10.1097/01.rhu.0000260637.95695.40

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  4 in total

Review 1.  Lupoid sclerosis.

Authors:  Briele Keiserman; Luiz Fernando Garcias da Silva; Mauro W Keiserman; Carlos Alberto von Mühlen; Henrique Luiz Staub
Journal:  Rheumatol Int       Date:  2009-10-14       Impact factor: 2.631

Review 2.  Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

3.  Similarity of autoimmune diseases based on the profile of immune complex antigens.

Authors:  Miyako Baba; Kunihiro Ichinose; Mami Tamai; Atsushi Kawakami; Kaname Ohyama
Journal:  Rheumatol Int       Date:  2018-11-13       Impact factor: 2.631

Review 4.  Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.

Authors:  Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Front Neurol       Date:  2018-11-26       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.